Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation

Summary

Von Willebrand factor (vWF) plays an essential role in platelet adhesion and thrombus formation. Patients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 antigen levels compared to controls. Little is known about vWF and ADAMTS13 in AF patients treated with cardioversion (CV). Thus we investigated the alterations of plasma vWF and ADAMTS13 after CV and evaluated the predictive value of these parameters for recurrence of AF. In this observational study we determined plasma levels of vWF and ADAMTS13 in 77 patients before and immediately after CV, as well as 24 hours (h) and six weeks thereafter, by means of commercially available assays. The vWF/ ADAMTS13-ratio was significantly elevated immediately after CV (p=0.02) and 24 h after CV (p=0.002) as compared to baseline levels. ADAMTS13, 24 h after CV, exhibited a significant association with recurrence of AF (HR: 0.97; p=0.037). Accordingly, tertiles of ADAMTS13 showed a stepwise inverse correlation with the risk of recurrent AF (HR: 0.50; p=0.009). After adjustment for confounders, ADAMTS13 remained significant as an independent predictor of recurrent AF (HR: 0.61; p=0.047). Similarly, the vWF/ADAMTS13-ratio, 24 h after CV, was associated with rhythm stability and remained an independent predictor of recurrent AF (HR: 1.88; p=0.028). The regulation of vWF and its cleaving protease ADAMTS13 after CV might play a critical role in producing a pro-thrombotic milieu immediately after CV for AF. Since ADAMTS13 plasma concentration and the vWF/ADAMTS13-ratio are independently associated with rhythm stability, these indexes might be used for prediction of recurrence of AF.

Keywords

ADAMS/ADAMTS 13 - von Willebrand factor - atrial fibrillation - cardio-version - endothelial dysfunction

• References

• 1 Fuster V, Ryden LE, Cannom DS. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
• 2 Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32: 803-808.
• 3 Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardio-version of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 1998; 82: 1545-1547 A8.
• 4 Grimm RA, Stewart WJ, Maloney JD. et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22: 1359-1366.
• 5 Oltrona L, Broccolino M, Merlini PA. et al. Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation 1997; 95: 2003-2006.
• 6 Coll-Vinent B, Monteagudo J, Miro O. et al. Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation. Thromb Res 2006; 117: 235-240.
• 7 Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186-1193.
• 8 Chauhan AK, Kisucka J, Brill A. et al. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 2008; 205: 2065-2074.
• 9 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII:von Wille-brand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
• 10 Furlan M, Robles R, Solenthaler M. et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
• 11 Uemura T, Kaikita K, Yamabe H. et al. Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation. Thromb Res 2009; 124: 28-32.
• 12 Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS. et al. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol 1999; 84: 147R-151R.
• 13 Wyse DG, Waldo AL, DiMarco JP. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
• 14 Le Heuzey JY, Paziaud O, Piot O. et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004; 147: 121-126.
• 15 Stewart S, Murphy NF, Walker A. et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286-292.
• 16 Van Gelder IC, Crijns HJ, Tieleman RG. et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156: 2585-2592.
• 17 Tveit A, Seljeflot I, Grundvold I. et al. Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation. Thromb Res 2008; 121: 447-453.
• 18 Opolski G, Torbicki A, Kosior D. et al. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study. Kardiol Pol 2003; 59: 1-16.
• 19 Fatkin D, Kuchar DL, Thorburn CW. et al. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for “atrial stunning” as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23: 307-316.
• 20 Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994; 23: 961-969.
• 21 Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol 1996; 78: 435-439.
• 22 Lip GY, Rumley A, Dunn FG. et al. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol 1995; 51: 245-251.
• 23 Jacob K, Talwar S, Copplestone A. et al. Activation of coagulation occurs after electrical cardioversion in patients with chronic atrial fibrillation despite optimal anticoagulation with warfarin. Int J Cardiol 2004; 95: 83-88.
• 24 Nikitovic D, Zacharis EA, Manios EG. et al. Plasma Levels of Nitrites/Nitrates in Patients with Chronic Atrial Fibrillation are Increased after Electrical Restoration of Sinus Rhythm. J Interv Card Electrophysiol 2002; 7: 171-176.
• 25 Katoh H, Shimada T, Inoue S. et al. Reduced high serum hepatocyte growth factor levels after successful cardioversion in patients with atrial fibrillation. Clin Exp Pharmacol Physiol 2004; 31: 145-151.
• 26 Li-Saw-Hee FL, Blann AD, Gurney D. et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 2001; 22: 1741-1747.
• 27 Bernardo A, Ball C, Nolasco L. et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-106.
• 28 Conway DS, Buggins P, Hughes E. et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43: 2075-2082.
• 29 Crawley JT, Lam JK, Rance JB. et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 1085-1093.
• 30 Heppell RM, Berkin KE, McLenachan JM. et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77: 407-411.
• 31 Conway DS, Pearce LA, Chin BS. et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-3145.
• 32 Matsukawa M, Kaikita K, Soejima K. et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007; 100: 758-763.
• 33 Crawley JT, Lane DA, Woodward M. et al. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008; 6: 583-588.
• 34 Chion CK, Doggen CJ, Crawley JT. et al. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007; 109: 1998-2000.
• 35 Gombos T, Mako V, Cervenak L. et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009; 102: 573-580.
• 36 Miura M, Kaikita K, Matsukawa M. et al. Prognostic value of plasma von Wille-brand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost 2010; 103: 623-629.
• 37 Conway DS, Buggins P, Hughes E. et al. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004; 94: 508-510.
• 38 Kaireviciute D, Blann AD, Balakrishnan B. et al. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost 2010; 104: 122-127.
• 39 Mannucci PM, Canciani MT, Forza I. et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
• 40 Bongers TN, Emonts M, de Maat MP. et al. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thromb Haemost 2010; 103: 1181-1187.
• 41 Claus RA, Bockmeyer CL, Budde U. et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-247.
• 42 Kourliouros A, Savelieva I, Kiotsekoglou A. et al. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009; 157: 243-252.
• 43 Liu T, Li G, Li L. et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007; 49: 1642-1648.